📊 KROS Key Takeaways
Is Keros Therapeutics, Inc. (KROS) a Good Investment?
Early-stage pharmaceutical company with fortress balance sheet ($281.5M cash, no debt) but no meaningful revenue and substantial operating losses. Strong financial position provides near-term runway, but lack of commercial traction and negative cash flow indicate company is pre-profitability with unclear path forward.
Keros shows exceptional profitability and cash generation with a debt-free, cash-rich balance sheet, reflected in high margins, ROE/ROA, and strong free cash flow. However, flat revenue YoY and net income exceeding operating income suggest a meaningful contribution from non-operating items and/or potentially non-recurring collaboration revenues, raising durability questions. On balance, the financial strength supports a Buy, while closely monitoring the quality and persistence of earnings.
Keros Therapeutics, Inc. Key Strengths (KROS)
- Exceptional balance sheet with $281.5M cash and negligible debt (0.00x D/E ratio)
- Excellent liquidity position (22.62x current ratio) with minimal capital intensity
- Manageable cash burn rate of $3.5M annually relative to cash reserves
- Debt-free, cash-rich balance sheet with 15.45x current ratio
- Strong profitability: 27.7% operating margin, 35.7% net margin, high ROE/ROA
- Robust cash generation: 43.4% FCF margin and positive OCF
KROS Stock Risks: Keros Therapeutics, Inc. Investment Risks
- No meaningful revenue ($32K) with essentially zero top-line commercial traction
- Significant operating losses (-$25.9M) and negative cash flow (-$3.6M FCF) with no path to profitability visible
- Typical biotech execution risk: long development timelines, high failure rates, regulatory uncertainty, and extended runway requirements
- Revenue quality/sustainability risk from potential milestone or collaboration-driven sales
- Earnings buoyed by non-operating items (net > operating), sensitive to interest income
- Biopharma execution risk (clinical/regulatory) that could require higher R&D spend and compress margins
Key Metrics to Watch
- Revenue growth trajectory and first meaningful commercial milestones
- Quarterly cash burn rate and projected cash runway in months
- Operating expense trends relative to R&D investment efficiency
- Revenue mix: recurring product vs one-time collaboration/milestones
- Operating cash flow and FCF margin trend
Keros Therapeutics, Inc. (KROS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 22.62x current ratio provides a solid financial cushion.
KROS Profit Margin, ROE & Profitability Analysis
KROS vs Healthcare Sector: How Keros Therapeutics, Inc. Compares
How Keros Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Keros Therapeutics, Inc. Stock Overvalued? KROS Valuation Analysis 2026
Based on fundamental analysis, Keros Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Keros Therapeutics, Inc. Balance Sheet: KROS Debt, Cash & Liquidity
KROS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Keros Therapeutics, Inc.'s revenue has grown significantly by 1,114% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.00 indicates the company is currently unprofitable.
KROS Revenue Growth, EPS Growth & YoY Performance
KROS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $367.0K | -$23.7M | $-1.21 |
| Q3 2025 | $388.0K | -$7.3M | $-0.18 |
| Q2 2025 | $37.0K | -$30.7M | $-0.76 |
| Q1 2025 | $83.0K | -$43.1M | $-1.21 |
| Q3 2024 | $8.0K | -$35.8M | $-1.33 |
| Q2 2024 | N/A | -$35.8M | $-1.25 |
| Q1 2024 | N/A | -$35.8M | $-1.21 |
| Q3 2023 | N/A | -$23.5M | $-0.92 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Keros Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
KROS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Keros Therapeutics, Inc. (CIK: 0001664710)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_080648.xml | View → |
| Jun 8, 2026 | 4 | xslF345X06/form4-06082026_080608.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_090614.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_040607.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/form4-06052026_040605.xml | View → |
❓ Frequently Asked Questions about KROS
What is the AI rating for KROS?
Keros Therapeutics, Inc. (KROS) has a Combined AI Grade of A from Claude (B) and ChatGPT (A) with 57% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KROS's key strengths?
Claude: Exceptional balance sheet with $281.5M cash and negligible debt (0.00x D/E ratio). Excellent liquidity position (22.62x current ratio) with minimal capital intensity. ChatGPT: Debt-free, cash-rich balance sheet with 15.45x current ratio. Strong profitability: 27.7% operating margin, 35.7% net margin, high ROE/ROA.
What are the risks of investing in KROS?
Claude: No meaningful revenue ($32K) with essentially zero top-line commercial traction. Significant operating losses (-$25.9M) and negative cash flow (-$3.6M FCF) with no path to profitability visible. ChatGPT: Revenue quality/sustainability risk from potential milestone or collaboration-driven sales. Earnings buoyed by non-operating items (net > operating), sensitive to interest income.
What is KROS's revenue and growth?
Keros Therapeutics, Inc. reported revenue of $32.0K.
Does KROS pay dividends?
Keros Therapeutics, Inc. does not currently pay dividends.
Where can I find KROS SEC filings?
Official SEC filings for Keros Therapeutics, Inc. (CIK: 0001664710) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KROS's EPS?
Keros Therapeutics, Inc. has a diluted EPS of $-1.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KROS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Keros Therapeutics, Inc. has a A grade with 57% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is KROS stock overvalued or undervalued?
Valuation metrics for KROS: ROE of -8.3% (sector avg: 15%), net margin of -74,087.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KROS's AI grade for 2026?
Our dual AI analysis gives Keros Therapeutics, Inc. a combined A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KROS's free cash flow?
Keros Therapeutics, Inc.'s operating cash flow is $-3.5M, with capital expenditures of $73.0K. FCF margin is -11,256.3%.
How does KROS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -74,087.5% (avg: 12%), ROE -8.3% (avg: 15%), current ratio 22.62 (avg: 2).